可切除局部晚期食管鳞状细胞癌新辅助免疫治疗的临床应用进展

doi:10.3760/cma.j.cn371439-20241009-00052

国际肿瘤学杂志 ›› 2025, Vol. 52 ›› Issue (5): 309-314.doi: 10.3760/cma.j.cn371439-20241009-00052

可切除局部晚期食管鳞状细胞癌新辅助免疫治疗的临床应用进展

孙玉娇¹, 于美丽², 马文静³, 孙龙美¹, 朱兆峰¹, 郑媛媛¹()

¹青岛大学附属泰安市中心医院放疗科，泰安 271000
²青岛大学附属泰安市中心医院超声介入科，泰安 271000
³泰安市第一人民医院肿瘤血液内科，泰安 271000

收稿日期:2024-10-09 修回日期:2024-12-04 出版日期:2025-05-08 发布日期:2025-06-24
通讯作者: 郑媛媛 E-mail:yuanbao0812@163.com
基金资助:
泰安市科技创新发展项目(2021NS390)

Advances in the clinical application of neoadjuvant immunotherapy for resectable locally advanced esophageal squamous cell carcinoma

Sun Yujiao¹, Yu Meili², Ma Wenjing³, Sun Longmei¹, Zhu Zhaofeng¹, Zheng Yuanyuan¹()

¹Department of Radiation Oncology， Affiliated Tai'an City Central Hospital of Qingdao University， Tai'an 271000， China
²Department of Ultrasound Intervention， Affiliated Tai'an City Central Hospital of Qingdao University， Tai'an 271000， China
³Department of Oncology and Hematology， First People's Hospital of Tai'an， Tai'an 271000， China

Received:2024-10-09 Revised:2024-12-04 Online:2025-05-08 Published:2025-06-24
Contact: Zheng Yuanyuan E-mail:yuanbao0812@163.com
Supported by:
Tai'an City Science and Technology Innovation Development Project(2021NS390)

摘要/Abstract

摘要：

中国食管癌病例占全球的50%以上，其中大约90%的组织学亚型是鳞状细胞癌。食管癌患者初诊时50%以上已处于局部晚期或晚期，单纯手术治疗R0切除率较低，易发生局部复发和远处转移，患者5年生存率较低。近年来，食管癌新辅助治疗已受到学者们的广泛关注，但目前最有效的新辅助治疗类型仍不确定。免疫治疗是目前肿瘤治疗中最活跃的研究领域，进一步探索免疫治疗联合新辅助化疗或放化疗治疗模式有望提升局部可切除晚期食管鳞状细胞癌的治疗效果和生存获益。

关键词: 食道鳞癌, 新辅助治疗, 免疫疗法

Abstract:

Esophageal cancer cases in China account for more than 50% of the world， among which approximately 90% are histological subtypes of esophageal squamous cell carcinoma. Over 50% of esophageal cancer patients are initially diagnosed at locally advanced or advanced stages. The R0 resection rate with surgical treatment alone is relatively low， and local recurrence and distant metastasis are prone to occur， resulting in a low 5-year survival rate. Recent research has focused on neoadjuvant therapy for esophageal cancer， but the most effective form of such therapy remains undetermined. Immunotherapy is currently the most active research field in tumor treatment. Further exploration of the treatment model combing immunotherapy with neoadjuvant chemotherapy or chemoradiotherapy is expected to improve the therapeutic effect and survival benefit in patients with locally advanced resectable esophageal squamous cell carcinoma.

Key words: Esophageal squamous cell carcinoma, Neoadjuvant therapy, Immunotherapy

孙玉娇, 于美丽, 马文静, 孙龙美, 朱兆峰, 郑媛媛. 可切除局部晚期食管鳞状细胞癌新辅助免疫治疗的临床应用进展[J]. 国际肿瘤学杂志, 2025, 52(5): 309-314.

Sun Yujiao, Yu Meili, Ma Wenjing, Sun Longmei, Zhu Zhaofeng, Zheng Yuanyuan. Advances in the clinical application of neoadjuvant immunotherapy for resectable locally advanced esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2025, 52(5): 309-314.

参考文献 45

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
[2]	Zhang R, Lau LHS, Wu PIC, et al. Endoscopic diagnosis and treatment of esophageal squamous cell carcinoma[J]. Methods Mol Biol, 2020, 2129: 47-62. DOI: 10.1007/978-1-0716-0377-2_5. pmid: 32056169
[3]	An L, Li M, Jia Q. Mechanisms of radiotherapy resistance and radiosensitization strategies for esophageal squamous cell carcinoma[J]. Mol Cancer, 2023, 22(1): 140. DOI: 10.1186/s12943-023-01839-2.
[4]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管鳞状细胞癌新辅助放射治疗专家共识[J]. 国际肿瘤学杂志, 2023, 50(3): 129-137. DOI: 10.3760/cma.j.cn371439-20230217-00027.
[5]	Demarest CT, Chang AC. The landmark series: multimodal therapy for esophageal cancer[J]. Ann Surg Oncol, 2021, 28(6): 3375-3382. DOI: 10.1245/s10434-020-09565-5. pmid: 33629251
[6]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30. DOI: 10.3322/caac.21590.
[7]	山东省医学会肺癌食管癌多学科联合委员会. 山东省医学会食管癌多学科规范化诊疗指南(2023年版)[J]. 国际肿瘤学杂志, 2023, 50(7): 385-397. DOI: 10.3760/cma.j.cn371439-20230612-00077.
[8]	Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study[J]. Lancet, 2021, 398(10302): 759-771. DOI: 10.1016/S0140-6736(21)01234-4.
[9]	Luo H, Lu J, Bai Y, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial[J]. JAMA, 2021, 326(10): 916-925. DOI: 10.1001/jama.2021.12836. pmid: 34519801
[10]	Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 390(10111): 2461-2471. DOI: 10.1016/S0140-6736(17)31827-5.
[11]	Yagi T, Baba Y, Ishimoto T, et al. PD-L1 expression, tumor-infiltrating lymphocytes, and clinical outcome in patients with surgically resected esophageal cancer[J]. Ann Surg, 2019, 269(3): 471-478. DOI: 10.1097/SLA.0000000000002616. pmid: 29206673
[12]	O'Donnell JS, Hoefsmit EP, Smyth MJ, et al. The promise of neoadjuvant immunotherapy and surgery for cancer treatment[J]. Clin Cancer Res, 2019, 25(19): 5743-5751. DOI: 10.1158/1078-0432.CCR-18-2641. pmid: 31040150
[13]	Cui K, Hu S, Mei X, et al. Innate immune cells in the esophageal tumor microenvironment[J]. Front Immunol, 2021, 12: 654731. DOI: 10.3389/fimmu.2021.654731.
[14]	Zheng Y, Chen Z, Han Y, et al. Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment[J]. Nat Commun, 2020, 11(1): 6268. DOI: 10.1038/s41467-020-20019-0.
[15]	Yang W, Xing X, Yeung SJ, et al. Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma[J]. J Immunother Cancer, 2022, 10(1): e003497. DOI: 10.1136/jitc-2021-003497.
[16]	Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies[J]. Nat Rev Drug Discov, 2019, 18(3): 197-218. DOI: 10.1038/s41573-018-0007-y. pmid: 30610226
[17]	Chen X, Zhang W, Qian D, et al. Chemoradiotherapy-induced CD4⁺ and CD8⁺ T-cell alterations to predict patient outcomes in esophageal squamous cell carcinoma[J]. Front Oncol, 2019, 9: 73. DOI: 10. 3389/fonc.2019.00073. pmid: 30828566
[18]	Wang Y, Liu ZG, Yuan H, et al. The reciprocity between radiotherapy and cancer immunotherapy[J]. Clin Cancer Res, 2019, 25(6): 1709-1717. DOI: 10.1158/1078-0432.CCR-18-2581. pmid: 30413527
[19]	Zhang Z, Liu X, Chen D, et al. Radiotherapy combined with immunotherapy: the dawn of cancer treatment[J]. Signal Transduct Target Ther, 2022, 7(1): 258. DOI: 10.1038/s41392-022-01102-y.
[20]	Zhang W, Pang Q, Zhang X, et al. Programmed death-ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor[J]. Cancer Sci, 2017, 108(4): 590-597. DOI: 10.1111/cas.13197.
[21]	Lim SH, Hong M, Ahn S, et al. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer[J]. Eur J Cancer, 2016, 52: 1-9. DOI: 10.1016/j.ejca.2015.09.019. pmid: 26623522
[22]	Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer[J]. Nature, 2015, 520(7547): 373-377. DOI: 10.1038/nature14292.
[23]	Gong J, Le TQ, Massarelli E, et al. Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination[J]. J Immunother Cancer, 2018, 6(1): 46. DOI: 10. 1186/s40425-018-0361-7.
[24]	Wen J, Fang S, Hu Y, et al. Impacts of neoadjuvant chemoradiotherapy on the immune landscape of esophageal squamous cell carcinoma[J]. EBioMedicine, 2022, 86: 104371. DOI: 10.1016/j.ebiom. 2022.104371.
[25]	Pauken KE, Sammons MA, Odorizzi PM, et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade[J]. Science, 2016, 354(6316): 1160-1165. DOI: 10. 1126/science.aaf2807. pmid: 27789795
[26]	Lu Z, Wang J, Shu Y, et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial[J]. BMJ, 2022, 377: e068714. DOI: 10.1136/bmj-2021-068714.
[27]	Wang ZX, Cui C, Yao J, et al. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial[J]. Cancer Cell, 2022, 40(3): 277-288.e3. DOI: 10.1016/j.ccell.2022.02.007.
[28]	Shang X, Zhao G, Liang F, et al. Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage Ⅲ) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-Ⅱ trial (Keystone-001)[J]. Ann Transl Med, 2022, 10(4): 229. DOI: 10.21037/atm-22-513.
[29]	Jing SW, Zhai C, Zhang W, et al. Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: a propensity score matching[J]. Front Immunol, 2022, 13: 970534. DOI: 10.3389/fimmu.2022.970534.
[30]	Yang Y, Liu J, Liu Z, et al. Two-year outcomes of clinical N_2-3 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study[J]. J Thorac Cardiovasc Surg, 2024, 167(3): 838-847.e1. DOI: 10.1016/j.jtcvs. 2023.08.056.
[31]	Zhang B, Zhao H, Wu X, et al. Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer[J]. Front Immunol, 2023, 14: 1066527. DOI: 10.3389/fimmu.2023.1066527.
[32]	Yang P, Zhou X, Yang X, et al. Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study[J]. World J Surg Oncol, 2021, 19(1): 333. DOI: 10.1186/s12957-021-02446-5.
[33]	Zhang Z, Ye J, Li H, et al. Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: a prospective, single-arm, phase 2 trial[J]. Front Immunol, 2022, 13: 1031171. DOI: 10.3389/fimmu.2022.1031171.
[34]	Lv H, Huang C, Li J, et al. The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma[J]. Front Immunol, 2022, 13: 1100750. DOI: 10.3389/fimmu.2022.1100750.
[35]	Chen X, Xu X, Wang D, et al. Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial[J]. J Immunother Cancer, 2023, 11(2): e005830. DOI: 10. 1136/jitc-2022-005830.
[36]	Xu J, Kato K, Raymond E, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2023, 24(5): 483-495. DOI: 10.1016/S1470-2045(23)00108-0. pmid: 37080222
[37]	Yan X, Duan H, Ni Y, et al. Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: a prospective, single-arm, phase Ⅱ study (TD-NICE)[J]. Int J Surg, 2022, 103: 106680. DOI: 10.1016/j.ijsu.2022.106680.
[38]	He W, Leng X, Mao T, et al. Toripalimab plus paclitaxel and carboplatin as neoadjuvant therapy in locally advanced resectable esophageal squamous cell carcinoma[J]. Oncologist, 2022, 27(1): e18-e28. DOI: 10.1093/oncolo/oyab011.
[39]	Zhang G, Yuan J, Pan C, et al. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial[J]. EBioMedicine, 2023, 90: 104515. DOI: 10.1016/j.ebiom.2023.104515.
[40]	Eyck BM, Hulshof MCCM, et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial[J]. J Clin Oncol, 2021, 39(18): 1995-2004. DOI: 10.1200/JCO.20.03614.
[41]	Yang H, Liu H, Chen Y, et al. Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: the NEOCRTEC5010 randomized clinical trial[J]. JAMA Surg, 2021, 156(8): 721-729. DOI: 10.1001/jamasurg.2021.2373. pmid: 34160577
[42]	Chen R, Liu Q, Li Q, et al. A phase Ⅱ clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901)[J]. EClinicalMedicine, 2023, 62: 102118. DOI: 10.1016/j.eclinm.2023. 102118.
[43]	Jiang N, Zhang J, Guo Z, et al. Short-course neoadjuvant radiotherapy combined with chemotherapy and toripalimab for locally advanced esophageal squamous cell carcinoma (SCALE-1): a single-arm phase Ⅰb clinical trial[J]. J Immunother Cancer, 2024, 12(1): e008229. DOI: 10.1136/jitc-2023-008229.
[44]	Li C, Zhao S, Zheng Y, et al. Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)[J]. Eur J Cancer, 2021, 144: 232-241. DOI: 10. 1016/j.ejca.2020.11.039. pmid: 33373868
[45]	Park SY, Hong MH, Kim HR, et al. The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma[J]. J Thorac Dis, 2020, 12(11): 6426-6434. DOI: 10.21037/jtd-20-1088. pmid: 33282345

可切除局部晚期食管鳞状细胞癌新辅助免疫治疗的临床应用进展

Advances in the clinical application of neoadjuvant immunotherapy for resectable locally advanced esophageal squamous cell carcinoma

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 45

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘山, 潘越, 张倬, 刘冲, 李雪曼, 熊飞. 二甲双胍通过调控ALKBH3的表达抑制食管鳞状细胞癌细胞生长、迁移和血管生成[J]. 国际肿瘤学杂志, 2025, 52(6): 343-352.
[2]	王旻, 温馨格, 魏毓正, 孙诚诚, 周婷婷. 纳武利尤单抗联合化疗治疗胃癌假性进展1例并文献复习[J]. 国际肿瘤学杂志, 2025, 52(6): 395-397.
[3]	吕晓岩, 王媛, 王军. 精准医学背景下的食管鳞状细胞癌放疗研究进展[J]. 国际肿瘤学杂志, 2025, 52(5): 268-272.
[4]	四川省抗癌协会食管癌专业委员会. 晚期食管鳞状细胞癌一线免疫治疗联合化疗进展后的诊疗策略——四川省专家共识[J]. 国际肿瘤学杂志, 2025, 52(5): 273-281.
[5]	刘海燕, 张超. 基于CT影像加权组学评分构建非小细胞肺癌的免疫治疗疗效预测模型[J]. 国际肿瘤学杂志, 2025, 52(4): 202-208.
[6]	刘前怡, 董洪敏, 王文玲, 王刚, 陈望花. 放疗联合化疗和免疫治疗对HER2阴性局部晚期或晚期胃癌的临床疗效和安全性[J]. 国际肿瘤学杂志, 2025, 52(4): 209-216.
[7]	文英美, 夏锦雄, 王园园, 姚颐. 放疗对抗肿瘤免疫的影响：从基础到临床[J]. 国际肿瘤学杂志, 2025, 52(4): 231-236.
[8]	王智颖, 盛立军. 外周血标志物在非小细胞肺癌免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2025, 52(3): 180-185.
[9]	王熙博, 田宝文, 陈士巧. Breg细胞在肿瘤免疫逃逸中的机制及相关治疗靶点[J]. 国际肿瘤学杂志, 2025, 52(2): 107-112.
[10]	陈茹雁, 付振明. 晚期肾细胞癌的免疫治疗现状与进展[J]. 国际肿瘤学杂志, 2025, 52(2): 124-128.
[11]	马培晗, 张灵敏, 李茜, 路宁, 温华, 张明鑫. ALKBH5对食管鳞状细胞癌恶性生物学行为的影响及相关机制研究[J]. 国际肿瘤学杂志, 2025, 52(2): 79-88.
[12]	吴晓维, 胡格, 陈莉, 钱晓涛, 崔相利, 朱凤琴. 放疗前肿瘤最大径、外周血NLR对食管鳞状细胞癌患者放疗后发生食管瘘的预测价值[J]. 国际肿瘤学杂志, 2025, 52(1): 38-42.
[13]	余洋, 唐仕敏, 杨露, 李娜. pT_2-3N₀M₀期胸段食管鳞状细胞癌治疗策略及预后影响因素研究进展[J]. 国际肿瘤学杂志, 2025, 52(1): 43-47.
[14]	黄镇, 晏菲, 马燕凌, 孙建海. 食管癌靶向及免疫治疗研究进展[J]. 国际肿瘤学杂志, 2025, 52(1): 53-59.
[15]	伍杨, 李甜, 张润兵, 史婷婷, 高春, 郑晓凤, 张久聪. 胃癌及食管胃结合部癌免疫及靶向治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(9): 595-600.